NEW
YORK, Sept. 27, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a
clinical stage biopharmaceutical company developing novel products
to treat brain health disorders, today announced that it intends to
offer and sell, subject to market conditions, common shares with
accompanying warrants to purchase common shares in an underwritten
public offering. All of the securities to be sold in the offering
will be offered by MindMed. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or the actual size or terms of the
offering. No distribution under the underwritten public offering
shall occur in Canada or to a
person resident in Canada.
RBC Capital Markets and Cantor are acting as lead joint
book-running managers for the offering. Oppenheimer & Co. is
acting as a joint book-running manager for the offering.
A shelf registration statement relating to the securities
offered in the public offering described above was filed with
the Securities and Exchange Commission ("SEC")
on May 4, 2022 and declared effective by the SEC on
May 16, 2022. The offering will
be made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and
will be available on the SEC's website at www.sec.gov or on
SEDAR at www.sedar.com. Copies of the preliminary prospectus
supplement and the accompanying prospectus, when available, may
also be obtained by contacting RBC Capital Markets, Attention:
Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877)
822-4089 or by email at equityprospectus@rbccm.com or by contacting
Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park
Avenue, 4th Floor, New York, NY
10022, or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders. We are developing a
pipeline of innovative drug candidates, with and without acute
perceptual effects, targeting the serotonin, dopamine and
acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to MindMed
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, the uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all. There are numerous risks and
uncertainties that could cause actual results and MindMed's plans
and objectives to differ materially from those expressed in the
forward-looking information, such as those risks discussed or
referred to herein and the risks described in MindMed's Annual
Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Report on
Form 10-Q for the period ended June 30,
2022 under headings such as "Special Note Regarding
Forward-Looking Statements," and "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and other filings and furnishings made by MindMed with
the securities regulatory authorities in all provinces and
territories of Canada which are
available under MindMed's profile on SEDAR at www.sedar.com and
with the SEC on EDGAR at www.sec.gov. Except as required by law,
MindMed undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-proposed-public-offering-of-common-shares-301634785.html
SOURCE Mind Medicine (MindMed) Inc.